Parabilis Medicines, Inc. (PBLS)
| Market Cap | 3.53B |
| Revenue (ttm) | 148,000 |
| Net Income | -231.67M |
| EPS | -23.45 |
| Shares Out | 123.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 629,323 |
| Open | 27.88 |
| Previous Close | 27.88 |
| Day's Range | 27.11 - 28.87 |
| 52-Week Range | 22.66 - 42.49 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 41.40 (+45.06%) |
| Est. Earnings | Nov 17, 2026 |
About PBLS
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-ca... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for PBLS stock is "Strong Buy." The 12-month stock price target is $41.4, which is an increase of 45.06% from the latest price.
News
Parabilis Medicines to Participate in Upcoming November Investor Conferences
CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serio...
Parabilis Medicines announces safety, efficacy data for zolucatetide
Parabilis Medicines (PBLS) announced updated safety and efficacy data for zolucatetide, the first and only direct inhibitor of the beta-catenin:TCF interaction, in patients with desmoid tumors. The da...
Parabilis Medicines Transcript: Investor update
Zolucatetide showed 72.2% ORR at week 32 and 100% disease control among response-evaluable patients starting at 450 mg or higher, with no progressions observed. FDA-aligned plans target PEDESTAL initiation in H1 2027 and top-line data in 2029.
Parabilis Medicines Slides: Investor update
Parabilis Medicines has posted slides in relation to its latest quarterly earnings report, which was published on October 24, 2026.
Parabilis Medicines Press release: Investor update
Parabilis Medicines issued a press release on October 24, 2026, disclosing material business information to investors.
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serio...
Parabilis Medicines initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Robert Burns initiated coverage of Parabilis Medicines (PBLS) with a Buy rating and $40 price target Parabilis is a clinical-stage biotechnology company pioneering innovative t...
Why Is Parabilis Medicines Stock (PBLS) Up 11% Today?
Parabilis Medicines stock was up on Monday following a clinical trial update and planned presentation.
Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026
Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid tumor...
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors
Parabilis Medicines rises 6.3%
Parabilis Medicines (PBLS) is up 6.3%, or $1.72 to $29.20.
Parabilis Medicines falls -12.5%
Parabilis Medicines (PBLS) is down -12.5%, or -$5.22 to $36.51.
Parabilis Medicines Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The Helicon platform enables targeting of undruggable proteins, with Zolucatetide showing strong efficacy and safety in desmoid tumors and promising early results in FAP and ACP. Phase III trials, pipeline expansion, and a Regeneron partnership are underway, supported by $1.1B in cash.
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with seri...
Parabilis Medicines appoints Craig Tendler to board of directors
Parabilis Medicines (PBLS) announced the appointment of Craig Tendler to its board of directors. Tendler has served as a scientific advisor to Parabilis Medicines, a role he will continue alongside…
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.
CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serio...
Parabilis Medicines reports Q2 EPS ($2.32), consensus (24c)
Reports Q2 revenue $148,000, consensus $16.67M. “This quarter marked meaningful progress toward our long-term vision as we continued advancing zolucatetide across multiple Wnt/beta-catenin-driven dise...
Parabilis Medicines Slides: Corporate presentation
Parabilis Medicines has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors
Parabilis Medicines Earnings release: Q2 2026
Parabilis Medicines released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Parabilis Medicines Quarterly report: Q2 2026
Parabilis Medicines has published its Q2 2026 quarterly earnings report on August 13, 2026.
Parabilis Medicines initiated with an Outperform at Leerink
Leerink initiated coverage of Parabilis Medicines (PBLS) with an Outperform rating and $40 price target The firm believes the company’s lead asset zolucatetide has the potential to be active across…
Parabilis Medicines initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of Parabilis Medicines (PBLS) with an Outperform rating and no price target Parabilis is “taking bold strides in drug development,” initial findings in desmoid tumors a...
Parabilis Medicines initiated with a Buy at BofA
BofA initiated coverage of Parabilis Medicines (PBLS) with a Buy rating and $45 price target Parabilis is advancing AI-enabled therapeutics for previously undruggable targets, with lead candidate zolu...
Parabilis Medicines initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Parabilis Medicines (PBLS) with a Buy rating and $40 price target The “Helicon platform” serves as a differentiated product engine and lead product candidate zolucatet...